Current Report Filing (8-k)
November 01 2017 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 1, 2017
EPIZYME, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-35945
|
|
26-1349956
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
400 Technology Square, Cambridge,
Massachusetts
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
229-5872
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 1, 2017, Epizyme, Inc.,
a Delaware corporation (the Company), announced its financial results for the quarter ended September 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form
8-K
and is incorporated herein by reference.
The information provided
under Item 2.02 of this Form
8-K
(including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On November 1, 2017, the Company announced that Peter T.C. Ho, M.D., Ph.D., the Companys Executive Vice President
and Chief Medical Officer, will be leaving the Company, effective December 31, 2017.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
*
|
The information in this exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
|
Date: November 1, 2017
|
|
|
|
By:
|
|
/s/ Robert B. Bazemore
|
|
|
|
|
|
|
Robert B. Bazemore
President and Chief
Executive Officer
|
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2023 to Apr 2024